Katie J Doores

List of Publications by Year
in descending order

78 papers	11,232 citations	57758 44 h-index	66911 78 g-index
110 all docs	110 docs citations	110 times ranked	16756 citing authors

#	ARTICLE	IF	CITATIONS
1	Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 2011, 477, 466-470.	27.8	1,397
2	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, 2020, 5, 1598-1607.	13.3	1,115
3	A dynamic COVID-19 immune signature includes associations with poor prognosis. Nature Medicine, 2020, 26, 1623-1635.	30.7	765
4	A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield. Science, 2011, 334, 1097-1103.	12.6	644
5	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncology, The, 2021, 22, 765-778.	10.7	491
6	Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity, 2014, 40, 657-668.	14.3	342
7	Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nature Medicine, 2020, 26, 1701-1707.	30.7	315
8	Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature Structural and Molecular Biology, 2013, 20, 796-803.	8.2	314
9	Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13800-13805.	7.1	309
10	Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans. PLoS Pathogens, 2013, 9, e1003342.	4.7	267
11	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Reports, 2016, 14, 2695-2706.	6.4	250
12	Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nature Communications, 2022, 13, .	12.8	243
13	Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16. Journal of Virology, 2010, 84, 10510-10521.	3.4	222
14	The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade. PLoS ONE, 2011, 6, e23521.	2.5	201
15	The effect of spike mutations on SARS-CoV-2 neutralization. Cell Reports, 2021, 34, 108890.	6.4	200
16	Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. Science Translational Medicine, 2014, 6, 236ra63.	12.4	160
17	Exploring and Exploiting the Therapeutic Potential of Glycoconjugates. Chemistry - A European Journal, 2006, 12, 656-665.	3.3	155
18	Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. Cell Host and Microbe, 2016, 20, 429-442.	11.0	154

#	Article	IF	Citations
19	Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell Reports, 2015, 11, 1604-1613.	6.4	135
20	The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatology, The, 2021, 3, e627-e637.	3.9	132
21	Defining Criteria for Oligomannose Immunogens for HIV Using Icosahedral Virus Capsid Scaffolds. Chemistry and Biology, 2010, 17, 357-370.	6.0	125
22	SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nature Communications, 2021, 12, 3406.	12.8	122
23	The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. Journal of Virology, 2021, 95, .	3.4	121
24	Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nature Communications, 2015, 6, 7479.	12.8	113
25	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity, 2021, 54, 1276-1289.e6.	14.3	112
26	Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe, The, 2021, 2, e461-e471.	7.3	109
27	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. Science Advances, 2021, 7, .	10.3	107
28	The <scp>HIV</scp> glycan shield as a target for broadly neutralizing antibodies. FEBS Journal, 2015, 282, 4679-4691.	4.7	106
29	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathogens, 2020, 16, e1008817.	4.7	105
30	A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17107-17112.	7.1	95
31	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nature Microbiology, 2021, 6, 1433-1442.	13.3	94
32	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell, 2021, 39, 257-275.e6.	16.8	93
33	Protein and Glycan Mimicry in HIV Vaccine Design. Journal of Molecular Biology, 2019, 431, 2223-2247.	4.2	91
34	Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope. Journal of Virology, 2015, 89, 8932-8944.	3.4	88
35	Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged. Journal of Virology, 2010, 84, 10690-10699.	3.4	80
36	Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV Envelope. Journal of Virology, 2015, 89, 1105-1118.	3.4	80

#	Article	IF	Citations
37	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathogens, 2015, 11, e1005110.	4.7	78
38	Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology, 2010, 20, 812-823.	2.5	77
39	Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Current Opinion in Virology, 2015, 11, 63-69.	5.4	73
40	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatology, The, 2022, 4, e42-e52.	3.9	66
41	The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate. Nature Immunology, 2021, 22, 1490-1502.	14.5	65
42	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. Journal of Infection, 2020, 81, 931-936.	3.3	59
43	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2) induces neutralising antibody and polyfunctional Tâ€cell responses in patients with chronic myeloid leukaemia. British Journal of Haematology, 2021, 194, 999-1006.	2.5	55
44	A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25057-25067.	7.1	53
45	Very Few Substitutions in a Germ Line Antibody Are Required To Initiate Significant Domain Exchange. Journal of Virology, 2010, 84, 10700-10707.	3.4	52
46	HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. Journal of Virology, 2016, 90, 11132-11144.	3.4	43
47	A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus. Cell Reports, 2018, 25, 3750-3758.e4.	6.4	41
48	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia, 2021, 35, 3573-3577.	7.2	41
49	Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies. Retrovirology, 2016, 13, 8.	2.0	40
50	The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans. Structure, 2017, 25, 773-782.e5.	3.3	39
51	Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. Journal of Virology, 2015, 89, 6952-6959.	3.4	35
52	SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. ELife, 2022, 11, .	6.0	34
53	Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7031-7036.	7.1	31
54	Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding. Analytical Chemistry, 2018, 90, 7325-7331.	6.5	31

#	ARTICLE	IF	CITATIONS
55	Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. Cancer Cell, 2021, 39, 1445-1447.	16.8	29
56	Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional TÂcell response in allogeneic stem cell transplantation recipients. Cancer Cell, 2021, 39, 1448-1449.	16.8	29
57	Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. MBio, 2022, 13, e0379821.	4.1	28
58	Reagent switchable stereoselective Î²(1,2) mannoside mannosylation: OH-2 of mannose is a privileged acceptor. Organic and Biomolecular Chemistry, 2008, 6, 2692.	2.8	27
59	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. Analyst, The, 2020, 145, 5638-5646.	3.5	26
60	SARS-CoV-2â€"specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. Journal of Clinical Investigation, 2022, 132, .	8.2	24
61	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clinical Microbiology and Infection, 2022, 28, 93-100.	6.0	21
62	Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein. ELife, 2020, 9, .	6.0	19
63	2G12-Expressing B Cell Lines May Aid in HIV Carbohydrate Vaccine Design Strategies. Journal of Virology, 2013, 87, 2234-2241.	3.4	18
64	ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type compositionâ€"implications for COVID-19. International Journal of Obesity, 2022, 46, 1478-1486.	3.4	18
65	â€œPolar patchâ€•proteases as glycopeptiligases. Chemical Communications, 2005, , 168-170.	4.1	14
66	Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen. MBio, 2021, 12, e0253120.	4.1	13
67	TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction. PLoS Pathogens, 2021, 17, e1009820.	4.7	13
68	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. Cell Reports, 2022, 39, 110757.	6.4	10
69	Translational Research in the Time of COVID-19â€"Dissolving Boundaries. PLoS Pathogens, 2020, 16, e1008898.	4.7	7
70	Contrasting Modes of New World Arenavirus Neutralization by Immunization-Elicited Monoclonal Antibodies. MBio, 2022, 13, e0265021.	4.1	7
71	Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib. Blood Cancer Journal, 2022, 12, 73.	6.2	7
72	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. PLoS ONE, 2021, 16, e0249791.	2.5	6

#	Article	IF	Citations
73	Harnessing post-translational modifications for next-generation HIV immunogens. Biochemical Society Transactions, 2018, 46, 691-698.	3.4	5
74	Targeting Glycans on Human Pathogens for Vaccine Design. Current Topics in Microbiology and Immunology, 2018, 428, 129-163.	1.1	5
75	BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes. Haematologica, 2022, 107, 1181-1184.	3.5	5
76	Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans. Cell Reports, 2022, 38, 110611.	6.4	3
77	Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients. Blood, 2021, 138, 3920-3920.	1.4	1
78	Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection SPARTAC cohort. Aids, 2021, Publish Ahead of Print, 2073-2084.	2.2	0